Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Non Freeze-Dried Live Attenuated Influenza Vaccine in Healthy People
NCT05284851Phase 2Unknown
- Sponsor
- Changchun BCHT Biotechnology Co.
- Start
- Apr 2022
- Primary completion
- May 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of live attenuated influenza vaccine in influenza (3 arms), sponsored by Changchun BCHT Biotechnology Co. Primary endpoint: Number of participants with positive sIgA at 10 days. Status: unknown.
02
Drugs
live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05284851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05284851.